Unravel Health
Developing an at-home saliva-testing device for continuous hormone and biomarker monitoring.
Website: https://www.unravel.health/
Cover Block
Public sources
| Field | Value |
|---|---|
| Name | Unravel Health |
| Tagline | Developing an at-home saliva-testing device for continuous hormone and biomarker monitoring. |
| Headquarters | London, United Kingdom [F6S] |
| Founded | 2024 [F6S] |
| Stage | Seed [Zinc VC, March 2025] |
| Business Model | Hardware + Software [Caplight] |
| Industry | Healthtech |
| Technology | Biotech / Life Sciences |
| Geography | Western Europe |
| Growth Profile | Venture Scale |
| Founding Team | Co-Founders (3+): Alexandra Oti, Liza Levy, Veronika Bridgman [Crunchbase] [LinkedIn] [RocketReach] |
| Funding Label | Seed, total disclosed approximately $321,250 [Caplight] |
Links
Public sources
- Website: https://www.unravel.health/pilot
Executive Summary
PUBLIC Unravel Health is a London-based healthtech startup developing an at-home saliva-testing device for continuous hormone and biomarker monitoring, and it merits attention because it is trying to turn a historically episodic testing workflow into a higher-frequency consumer and clinical data layer in women’s health [F6S] [Zinc VC, March 2025] [N24, October 2026]. Founded in 2024, the company appears to be commercializing measurement technology developed at the University of Glasgow over roughly a decade, with public materials pointing to three granted patents and an intended market launch from 2027 [WOMEN OF WEARABLES] [N24, October 2026].
The product, described publicly as a palm-sized home “Micro Lab,” is intended to read hormone levels from saliva and measure up to 16 biomarkers over time, with the company positioning that frequency as an advantage over one-off blood tests that can miss hormonal variation [LinkedIn, May 2025] [F6S] [Stevenage Bioscience Catalyst]. The initial use cases named in public sources, menstrual-cycle tracking, fertility, perimenopause, hormonal migraines, and related hormone-linked conditions, suggest a broad wedge, but they also imply a meaningful validation and go-to-market burden before the platform can support multiple clinical and consumer claims [LinkedIn, May 2025] [Stevenage Bioscience Catalyst].
The founding bench is stronger on domain adjacency than on publicly verified commercial traction: Alexandra Oti is identified as a co-founder and medical doctor with academic experience at Oxford and Cambridge, Liza Levy as a co-founder with prior healthcare startup scaling exposure, and Veronika Bridgman as co-founder and CEO with brand and strategy experience [Crunchbase] [Zinc VC, March 2025] [RocketReach] [Samuel Gebreselassie]. On capital, the public record shows grant support in 2024 and early 2025, Zinc backing in March 2025, and a £2.5 million equity round reported in October 2026 led by Conduit EIS Impact Fund and Wrightwood, with Leo Capital, Embryo Ventures, Hermesa, and Zinc VC also participating [Caplight] [LinkedIn, December 2024] [Zinc VC, March 2025] [N24, October 2026].
The business model is best read, at this stage, as a hardware-plus-software bet rather than a fully evidenced commercial motion, since public sources describe the product direction but do not yet verify customers, regulatory clearance, or scaled deployment [Caplight] [F6S] [N24, October 2026]. Over the next 12 to 18 months, the key watchpoints are whether Unravel can move from promising technical narrative to externally validated proof on device performance, regulatory path, and early customer adoption ahead of its stated 2027 launch window [LinkedIn, May 2025] [N24, October 2026].
Company-stated, unverified -- This section relies materially on company-linked and investor-linked sources, with limited independent public corroboration beyond funding coverage.
Taxonomy Snapshot
| Axis | Value |
|---|---|
| Stage | Seed |
| Business Model | Hardware + Software |
| Industry / Vertical | Healthtech |
| Technology Type | Biotech / Life Sciences |
| Geography | Western Europe |
| Growth Profile | Venture Scale |
| Founding Team | Co-Founders (3+) |
| Funding | Seed, total disclosed ~$321,250 |
How the Company Got Here
PUBLIC
What is verifiable in public records is still fairly narrow: Unravel Health appears to be an early-stage London company formed in 2024, built around a women’s health diagnostics concept rather than a product already in broad market use [Crunchbase] [F6S]. Public materials describe the company as developing an at-home saliva-testing device, branded "Micro Lab," for continuous hormone and biomarker monitoring, but those product details remain better treated as company-positioning than established commercial fact at this stage [F6S].
The founding team publicly named across company and profile sources includes Alexandra Oti, Liza Levy, and Veronika Bridgman [Crunchbase] [LinkedIn] [RocketReach]. Headquarters are listed in London, United Kingdom, and the company’s public web presence indicates an active pilot-oriented site rather than a mature commercial footprint [F6S] [Unravel Health].
The early timeline is visible in fragments rather than as a complete operating history. The company is listed as founded in 2024 [Crunchbase], surfaced publicly around grants and startup support activity in late 2024 and early 2025 [LinkedIn, December 2024] [Caplight], and by March 2025 appeared in Zinc VC’s founder spotlight as one of its science-for-impact ventures [Zinc VC, March 2025]. That sequence suggests a business still in company-building and validation mode, with the legal and organizational skeleton in place but limited public disclosure on entity structure or operating milestones beyond fundraising-related mentions [Crunchbase] [Unravel Health].
Lightly corroborated -- Founded year is supported by Crunchbase, and founder identities are partially corroborated across public profiles, but legal-entity detail and milestone chronology rely on partial public disclosure.
Product and Technology
Sources and analysis
The technical bet here is straightforward to describe even if the underlying evidence is still thin. Unravel Health says it is developing an at-home saliva-testing device, referred to publicly as a "Micro Lab," designed to measure multiple hormones and biomarkers over time rather than relying on one-off blood tests [F6S] [Zinc VC, March 2025]. Public descriptions characterize the device as palm-sized and non-invasive, with an intended ability to track up to 16 biomarkers and give users more granular visibility into hormonal fluctuations [LinkedIn, May 2025].
The public record also sketches the medical problem the company is trying to solve. According to company-linked and ecosystem sources, the platform is being built for daily or frequent monitoring of changing physiology, with initial use cases including menstrual-cycle tracking, fertility, perimenopause, hormonal migraines, and potentially improved understanding of conditions such as PMDD, thyroid, and autoimmune disorders [LinkedIn, May 2025] [Stevenage Bioscience Catalyst]. Those claims should still be read as developmental positioning rather than demonstrated clinical performance, because the material reviewed did not verify regulatory clearance, published trial results, or named commercial deployments.
What looks more durable, at least from the evidence available, is the origin of the measurement approach rather than the market claims around it. Multiple public sources tie the underlying technology to the University of Glasgow, and one source states the work was developed over ten years and is protected by three granted patents [LinkedIn, May 2025] [WOMEN OF WEARABLES]. Separately, Unravel has stated a planned market launch from 2027, which implies the current product remains in development or validation rather than broad release [N24, October 2026].
Company-stated, unverified -- Core product descriptions rely heavily on company-linked or ecosystem sources, with partial corroboration on the University of Glasgow origin from independent public materials.
Where the Demand Sits
PUBLIC
The market matters now because Unravel Health is trying to enter two categories that already attract real spending, home diagnostics and women’s health, while arguing that hormone measurement done once in a clinic misses the day-to-day variation that matters for many use cases [Zinc VC, March 2025] [Anne Roberts, May 2025].
The harder part is that no credible third-party market-sizing study was provided in the reviewed materials for continuous saliva-based hormone monitoring specifically, so any TAM framing here has to stay narrow and explicit. Public evidence supports only the existence of adjacent demand signals: home testing infrastructure, women’s health diagnostics, and consumer interest in longitudinal health data. That is enough to establish a plausible category backdrop, but not enough to quantify Unravel’s addressable market with discipline from the available record [F6S] [Zinc VC, March 2025].
What does surface clearly is the demand thesis. Unravel’s public positioning rests on an identifiable gap between one-off blood tests and recurring biomarker measurement, particularly for cycle tracking, fertility, perimenopause, hormonal migraines, PMDD, thyroid issues, and autoimmune-related monitoring claims referenced in company-linked materials and ecosystem write-ups [Zinc VC, March 2025] [Stevenage Bioscience Catalyst] [Samuel Gebreselassie]. That framing aligns with a broader healthcare shift toward earlier detection, home sampling, and more personalised care pathways, though the public materials do not yet verify payer adoption, provider contracts, or clinical deployment at scale [Caplight] [N24, October 2026].
Adjacent markets also matter because Unravel may end up selling into a blend of them rather than into a single diagnostics bucket. Depending on final product design and reimbursement strategy, the company could sit across consumer fertility tools, at-home diagnostics, chronic condition monitoring, and software layers that organise biomarker histories over time. Caplight classifies the business model possibilities broadly as hardware sales, subscription SaaS, and data-as-a-service, but that should be read as database taxonomy rather than a confirmed go-to-market plan from the company itself [Caplight].
Regulatory and macro forces cut both ways. On the supportive side, grant backing from SBRI Healthcare, the Health Innovation Network, the NHS Accelerated Access Collaborative, and validation support through the MedTech Innovation Fund suggest institutional interest in earlier-stage device concepts that could expand access and reduce reliance on episodic testing [Caplight] [Anne Roberts, May 2025]. The constraint is that a biomarker-monitoring device in healthtech is rarely judged on user interest alone: evidence standards, regulatory pathway, and clinical utility all shape adoption, and the reviewed public sources do not yet establish regulatory clearance, published trial data, or diagnostic-provider partnerships [Caplight].
| Market lens | What public sources support | Source quality |
|---|---|---|
| Core category | At-home saliva-testing device for continuous hormone and biomarker monitoring is the company’s stated product direction | Company-linked and ecosystem sources only [F6S] [Anne Roberts, May 2025] |
| Demand driver | Concern that snapshot blood tests miss hormonal fluctuation over time | Investor and ecosystem source support [Zinc VC, March 2025] [Stevenage Bioscience Catalyst] |
| Initial use cases | Menstrual-cycle tracking, fertility, perimenopause, hormonal migraines, faster identification of hormone-related conditions | Company-linked description repeated by ecosystem coverage [Anne Roberts, May 2025] |
| Institutional tailwind | Grant and program support tied to validation activity | Publicly cited support programs, but not equivalent to commercial traction [Caplight] [Anne Roberts, May 2025] |
| Market size | No named third-party TAM/SAM/SOM study surfaced in reviewed materials | No confirmed public sizing source in record |
The table makes the central point: there is a legible market narrative, but the public record is still stronger on problem definition than on quantified category size. For investors, that shifts diligence from top-down TAM slides toward bottom-up questions on test accuracy, regulatory path, buyer, and frequency of use.
Company-stated, unverified -- This section relies mainly on company-linked, investor, and ecosystem sources, with no independent third-party market-sizing report or verified commercial market data in the reviewed public record.
Competitive Landscape
MIXED Unravel Health is positioning itself less against a single named startup than against the standard care pathway of episodic hormone testing, symptom tracking, and clinic-led interpretation, which is a meaningful distinction but also a sign that the public record on direct rivals is still thin [Zinc VC, March 2025] [F6S].
The competitive map is easiest to read in layers. At the incumbent end, the practical alternative today is still one-off blood testing and conventional care workflows, which Unravel says miss hormonal variation over time and therefore under-describe cyclical conditions [Zinc VC, March 2025] [Stevenage Bioscience Catalyst]. Adjacent substitutes sit one step closer to the consumer, including symptom-tracking and fertility-oriented monitoring behaviors, because those already condition users to collect longitudinal health signals even if they do not measure saliva biomarkers directly [Anne Roberts, May 2025]. The challenger set is harder to name from public evidence, not because it does not exist, but because the sourced material here identifies no specific peer company by name, which leaves the category definition clearer than the competitor roster.
That absence matters because Unravel's public edge, at least for now, appears to rest more on technical origin than on distribution. The strongest differentiator supported in the record is that the underlying technology was developed over ten years at the University of Glasgow and is described as protected by three granted patents [WOMEN OF WEARABLES]. If that claim holds through productization, the defensibility could come from assay design, IP position, and the proprietary longitudinal dataset created by repeated at-home use. Even so, that edge is perishable until the company turns it into validated performance, regulatory progress, and a repeatable go-to-market motion, none of which are yet established in public sources [N24, October 2026] [Caplight].
The company's main exposure is less a named startup threat and more a channel problem. No public source reviewed here verifies commercial customers, deployed clinical partnerships, regulatory clearance, or an NHS customer relationship, despite grant-linked support from SBRI Healthcare, the Health Innovation Network, and the NHS Accelerated Access Collaborative [Caplight] [Anne Roberts, May 2025]. In practical terms, that means incumbents in diagnostics and established care providers still hold the physician, payer, and patient access points that matter if Unravel wants to move from an interesting device to a trusted clinical workflow. A company can own useful data collection without owning the interpretation layer or the reimbursement path.
The most plausible 18-month scenario is that the category winner is not the company with the most ambitious biomarker count, but the one that converts technical promise into credible validation first. Winner if X: Unravel Health, if it can show that a palm-sized saliva device measuring up to 16 biomarkers translates into reproducible data and a clear first use case such as fertility, perimenopause, or hormonal migraine management [Anne Roberts, May 2025] [N24, October 2026]. Loser if Y: Unravel Health, if the 2027 launch target slips and the company remains in a grant-supported validation posture while incumbents and adjacent digital health tools continue to capture user attention and clinician trust through already-established channels [N24, October 2026] [Caplight].
Opportunity
Upside case
PUBLIC If Unravel Health gets from prototype to routine at-home use, the prize is not a niche device sale but a new monitoring layer for hormone-linked care, one that could turn episodic testing into a repeat data stream across fertility, menstrual health, perimenopause, and adjacent chronic conditions [N24, October 2026] [LinkedIn, May 2025] [Zinc VC, March 2025].
The headline opportunity is straightforward: become the reference platform for longitudinal hormone and biomarker monitoring done outside the clinic. That sounds ambitious, but the public record at least gives the outline of a credible path. The company is not pitching a single-use test, according to public descriptions, it is developing a palm-sized saliva-testing device intended to measure up to 16 biomarkers over time, with an explicit argument that one-off blood tests miss meaningful hormonal variation [LinkedIn, May 2025] [F6S]. That matters because the commercial prize in diagnostics often sits less in the first reading than in repeat measurement, workflow integration, and the data layer that accumulates around ongoing use.
The reachability of that outcome rests on three public signals. First, the core technology is described as having been developed over ten years at the University of Glasgow and protected by three granted patents, which suggests the differentiation may sit in the sensing stack rather than only in the consumer interface [WOMEN OF WEARABLES]. Second, the company has already attracted grant support and later equity backing from Conduit EIS Impact Fund, Wrightwood, Leo Capital, Embryo Ventures, Hermesa, and Zinc VC, which is not proof of product-market fit but does indicate that early institutional backers see enough technical and market substance to fund the next stage [Caplight] [Zinc VC, March 2025] [N24, October 2026]. Third, the initial use cases span several recurring needs rather than a one-condition product, including menstrual-cycle tracking, fertility, perimenopause, and hormonal migraines [LinkedIn, May 2025]. That breadth can matter if one platform can support multiple wedges before the category settles.
| Scenario | What happens | Catalyst | Why it's plausible |
|---|---|---|---|
| Consumer monitoring wedge | Unravel launches in or after 2027 with an at-home device for repeat hormone tracking, wins an early consumer cohort in cycle, fertility, or perimenopause use cases, and builds a subscription-like monitoring model around recurring readings | Commercial launch from 2027 and a product experience that makes repeated saliva testing easier than clinic-based alternatives [N24, October 2026] | Public materials consistently describe the product as a non-invasive home device built for ongoing monitoring rather than one-off testing, and the stated use cases are all repeat-measurement categories [LinkedIn, May 2025] [F6S] |
| Clinical decision-support layer | The company moves from consumer utility into clinician-informed monitoring, using longitudinal biomarker data to support earlier identification of hormone-related conditions | Validation work through grant-backed programs and evidence that repeated monitoring captures patterns missed by snapshot tests [Caplight] [Stevenage Bioscience Catalyst] | Public sources tie the technology to conditions such as PMDD, hormonal migraines, thyroid and autoimmune disorders, and frame the product around information gaps in existing testing approaches [Stevenage Bioscience Catalyst] [Zinc VC, March 2025] |
| Women's health data platform | Unravel becomes the underlying data and sensing platform for partners in diagnostics, digital health, or care navigation, with the device and software acting as the intake layer for hormone-linked longitudinal data | A successful hardware launch plus partner interest in a patented measurement stack developed over a decade at the University of Glasgow [WOMEN OF WEARABLES] [N24, October 2026] | The company is positioning around continuous physiology tracking, not a single episodic assay, and public sources point to protected IP plus a biomarker set broader than one hormone [WOMEN OF WEARABLES] [LinkedIn, May 2025] |
The compounding logic here is a data flywheel, if the device works as described and users return regularly. Each additional reading improves the value of the personal baseline, makes the next reading more clinically interpretable, and can widen the set of supported use cases from cycle awareness into symptom correlation and condition identification. Public evidence only shows the earliest hints of this logic, namely that the company is explicitly built around daily or repeated measurement and around hormonal patterns that one-off blood tests can miss [Stevenage Bioscience Catalyst] [Zinc VC, March 2025]. In other words, the product thesis already assumes that time-series data, not a single result, is the scarce asset.
That same dynamic could create distribution advantages. A company that first wins a narrow use case such as fertility or perimenopause can, in principle, expand into adjacent conditions without replacing the hardware, provided the biomarker panel and interpretation layer support it. The public description of up to 16 biomarkers is relevant here because multi-analyte breadth can widen the product surface over time, even if the initial commercial entry point is narrower [LinkedIn, May 2025]. This is still a conditional flywheel, not an observed one, but it is the mechanism by which a home-testing device becomes infrastructure rather than a one-product business.
The size of the win is best framed as scenario analysis, not a forecast. Public sources provided for this report do not include a third-party market size study or a directly comparable public peer valuation, so a precise upside range would overstate what the evidence can bear. Even so, if the "women's health data platform" scenario plays out and Unravel becomes a trusted system for longitudinal hormone monitoring across several recurring categories, the company could plausibly graduate from a device startup into a strategic diagnostics or digital-health platform asset, because the value would sit in the repeat data layer, IP position, and multi-condition expansion path rather than in hardware margin alone [WOMEN OF WEARABLES] [N24, October 2026]. That is the version of the upside that matters: not simply selling tests, but owning the measurement relationship in an area where the incumbent standard appears intermittent and incomplete according to the company's public framing [Zinc VC, March 2025] [LinkedIn, May 2025].
Lightly corroborated -- This section relies on one independent news report, one investor profile, and several company-adjacent or company-originated product descriptions; the core upside logic is grounded, but major commercial claims remain pre-launch and only partially corroborated.
Sources
Public sources
[Zinc VC, March 2025] Founder spotlight: The women building Science-for-Impact ventures at Zinc | https://www.zinc.vc/blog/founder-spotlight-the-women-building-science-for-impact-ventures-at-zinc/
[LinkedIn, May 2025] medtech | https://www.linkedin.com/posts/anne-roberts79_medtech-activity-7328013537308549120-ggGf
[N24, October 2026] Unravel Health sichert sich 2,96 Millionen Euro | https://n24.com.tr/de/gesundheit/unravel-health-sichert-sich-296-millionen-euro-226
[LinkedIn, December 2024] Happy holidays amigos - here’s a rundown of what’s kept me busy over the… | https://www.linkedin.com/posts/lizalevy_happy-holidays-amigos-heres-a-rundown-activity-7277329533312069632-xh99
Articles about Unravel Health
- Unravel Health's Saliva Lab Aims to Map Hormones Daily — The London startup, with patents from a decade of university research, is developing a device to track up to 16 biomarkers from home.